Abstract
Despite the use of CTLA4 and PD1-PDL1-targeted cancer immunotherapy, a large proportion of patients with many tumor types fail to respond including uveal melanoma (UM). Targeting inhibitory immune checkpoint lymphocyte activation gene-3 (LAG3) in tumor microenvironment of UM holds promising potential. LAG3 (CD233) is an inhibitory receptor that plays a critical role in controlling T cell tolerance, preventing autoimmunity and limiting immune-mediated tissue damage. It is highly upregulated on exhausted T cells in tumors.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
